Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review
Open Access
- 7 June 2012
- journal article
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 269
Abstract
Background: Surgery followed by adjuvant chemotherapy has been the standard of care for the treatment of stage III colon cancer since the early 1990’s. Despite this, large proportions of patients do not receive adjuvant chemotherapy. We aimed to identify physicians’ and patients’ reasons for treatment decisions. Methods: A retrospective population based study was conducted that included all surgically treated stage III colon cancer patients diagnosed in Alberta between 2002 and 2005 who had an oncologist-consult to discuss post-surgical treatment options. Patient demographics and stage were obtained from the Alberta Cancer Registry. Chart reviews were conducted to extract treatment details, the oncologists’ reasons for not recommending chemotherapy, and patients’ reasons for refusing chemotherapy. The number and proportion of patients who were not recommended or refused chemotherapy were calculated. Results: A total of 613 patients had surgery followed by an oncologist-consult. Overall, 168 (27%) patients did not receive chemotherapy. It was not recommended for 111 (18%) patients; the most frequent reason was presence of one or more co-morbidities (34%) or combination of co-morbidity and age or frailty (22%). Fifty-eight (9%) patients declined chemotherapy, 22% of whom declined due to concerns about toxicity. Conclusion: Some co-morbidities are clinical indications for not receiving adjuvant chemotherapy, however, the high percentage of patients who were not recommended adjuvant chemotherapy due to co-morbidities according to clinical notes but who had a low Charlson co-morbidity score suggests variation in practice patterns of consulting oncologists. In addition, patients’ reasons for refusing treatment need to be systematically assessed to ensure patients’ preferences and treatment benefits are properly weighed when making treatment decisions.Keywords
This publication has 27 references indexed in Scilit:
- Comorbidities Alone Do Not Explain the Undertreatment of Colorectal Cancer in Older Adults: A French Population‐Based StudyJournal of the American Geriatrics Society, 2011
- Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, CanadaCancer, 2011
- Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline‐recommended treatmentCancer, 2010
- Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity?Journal of Clinical Oncology, 2008
- Across-province standardization and comparative analysis of time-to-care intervals for cancerBMC Cancer, 2007
- The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancerCancer, 2007
- Age, Sex, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal CancerJournal of Clinical Oncology, 2002
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancerBritish Journal of Surgery, 1987